PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
28218209-10	2017	Inhalation of iloprost resulted in similar changes in mean blood pressure, mPAP, PVR, systemic vascular resistance, CO, arterial oxygen saturation (SaO2), mixed venous oxygen saturation, partial pressure of oxygen in arterial blood (PaO2), PvO2, and intrapulmonary shunt (Qs/Qt) in the PAH and CTEPH groups (all P > 0.05).	Iloprost	14-22	phospholipid phosphatase 1	Mus musculus	75-79	
11583893-8	2001	Iloprost inhalation significantly decreased mPAP (-9.1 +/- 2.5 mm Hg vs. -7.9 +/- 1.5 mm Hg), PVR (-453 +/- 103 dyne.s.cm(-5) vs. -381 +/- 114 dyne.s.cm(-5)), ANP (-99 +/- 63 pg/ml vs. -108 +/- 47 pg/ml) and cGMP (-4.6 +/- 0.9 nM vs. -4.2 +/- 1.6 nM).	Iloprost	0-8	phospholipid phosphatase 1	Mus musculus	44-48	
35514784-7	2022	In a comparison of pre-inhalation values at the first and follow-up RHCs, inhaled iloprost significantly improved mean pulmonary artery pressure (mPAP; 39.9 +- 7.8 to 32.5 +- 7.2 mmHg, p = 0.016) and pulmonary vascular resistance (PVR; 588.5 +- 191.7 to 464.4 +- 188.5 dyn s cm-5, p = 0.047).	Iloprost	82-90	phospholipid phosphatase 1	Mus musculus	146-150	
25992279-8	2015	In summary, nebulized iloprost delivered via the I-neb AAD system reduced mPAP and PVR and increased CI from baseline in a heterogeneous group of patients with PH and in the subset with iPAH.	Iloprost	22-30	phospholipid phosphatase 1	Mus musculus	74-78	
16242948-7	2005	RESULTS: Iloprost significantly enhanced cardiac index (CI) and reduced mean pulmonary arterial pressure (mPAP) and pulmonary vascular resistance [PVR (dynscm(-5))] in contrast to placebo.	Iloprost	9-17	phospholipid phosphatase 1	Mus musculus	106-110	
18503929-9	2008	However, in a direct comparison, iloprost caused significantly greater reductions in PVR (p = 0.013) and mPAP (p = 0.0006) and a significantly greater increase in cardiac output (p = 0.002) compared with iNO.	Iloprost	33-41	phospholipid phosphatase 1	Mus musculus	105-109	
24562636-6	2014	After iloprost inhalation, the patients with low SLEDAI had a greater decrease in mPAP and PVR than those with high SLEDAI, while significantly increased RV systolic function was found only in the low-SLEDAI group.	Iloprost	6-14	phospholipid phosphatase 1	Mus musculus	82-86	
17804899-12	2008	RESULTS: Significant changes in pulmonary and systemic hemodynamics were observed following the inhalation of iloprost (before to after inhalation): PVR: 1,057 +/- 404.3 to 821.3 +/- 294.3 dyn.s.cm(-5), p < 0.0001; mPAP: 50.55 +/- 8.43 to 45.75 +/- 8.09 mm Hg, p = 0.0002; CO: 3.66 +/- 1.05 to 4.05 +/- 0.91 l/min, p < 0.0106.	Iloprost	110-118	phospholipid phosphatase 1	Mus musculus	218-222	
12963183-6	2003	Postoperatively, inhaled iloprost induced a significant reduction of mPAP and PVR and a significant increase of CI at T2 and T3.	Iloprost	25-33	phospholipid phosphatase 1	Mus musculus	69-73